I was moderating the lung cancer sessions yesterday and today. Lung cancer this year was very, very exciting because you have lots of new treatments, a new approach for the patient, so we have really good reviews about what we have.

We don’t have all these kinds of drugs in Brazil so it’s really important for Brazilian oncologists to hear from people that work with the new drugs, their experience. Especially yesterday we had a panel with surgeons, radio-oncologists and also pneumologists and this kind of multidisciplinary approach is really important. So I would point out these new drugs, new approach to the patient, that they are coming to Brazil next year and also this kind of multidisciplinary approach based on clinical case, these kinds of rich discussions where you put the experience of the whole team.